Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Discovery may help provide clues for fighting and treating HPV
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. Their findings, published online today in the journal Cell, may eventually help to broaden the scope of defenses against HPV and provide valuable clues for delivering drugs into cells. HPV is a family of killers. Although there are effective vaccines against these viruses, they still cause about 5% of cancer deaths worldwide, including more than 250,000 women who die of cervical cancer each year.
New compound targets drug-resistant HIV mutants
Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications.
Viral Suppression Helps Lower Risk for Many Types of Cancer, Study Finds.
A new study by the Yale School of Public Health and partner institutions is the first to examine the potential cancer prevention benefits of prolonged periods of HIV viral suppression, resulting from antiretroviral therapy, for persons living with HIV.
High rates of HIV and diabetes raise the risk of TB for South Africans
Since the 1980s, HIV has contributed to an increase in tuberculosis (TB) cases across the globe. Recently, diabetes has been found to be an important risk factor for TB. In a new study, Yale researchers investigated whether having both HIV and diabetes increases the risk of developing TB among individuals living in rural South Africa.
A Zika Vaccine Could Virtually Eliminate Prenatal Infections
A Zika vaccine could have a substantial effect on mitigating and preventing future Zika virus outbreaks. Through a combination of direct protection and indirect reduction of transmissions, virtual elimination is achievable, even with imperfect vaccine efficacy and coverage, a new Yale School of Public Health study finds.
Study explores new strategy to develop a malaria vaccine
A serum developed by Yale researchers reduces infection from malaria in mice, according to a new study. It works by attacking a protein in the saliva of the mosquitos infected with the malaria parasite rather than the parasite itself. If the novel approach proves effective in further studies, it could potentially be used to enhance existing malaria vaccines, the researchers said.
Study: Topical antibiotic triggers unexpected antiviral response
A Yale-led research team made a startling discovery while investigating the effect of bacteria on viral infections. When they applied a common topical antibiotic to mice before or shortly after infection with herpes and other viruses, they found that the antibiotic triggered an antiviral resistance in the animals, the researchers said.